Identifications of pancreatic cancer specific neo-antigens with the autoantibodiomics and verifications of diagnostic utilities of its autoantibody screening to neo-antigens

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07928
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: Osaka Medical and Pharmaceutical University
• Principal Investigator: NAKANISHI TOYOFUMI 大阪医科薬科大学, 研究支援センター, 准教授 (10247843)
• Co-Investigator(Kenkyū-buntansha): 高折 恭一 京都大学, 医学研究科, 准教授 (10329485) ; 増井 俊彦 京都大学, 医学研究科, 准教授 (20452352) ; 五十嵐 一雄 近畿大学, 医学部, 非常勤講師 (80098467) ; 松村 洋子 (田伏洋子) 大阪医科薬科大学, 医学部, 講師 (80388256)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 膵臓癌診断マーカー / 特異抗原 / 自己抗体 / 自己抗体スクリーニング / 検査診断技術

Outline of Final Research Achievements

A human pancreatic cancer cultured cell soluble fraction was used as a pancreatic cancer-specific antigen, a pancreatic disease patient serum was used as a primary antibody, a specific band was found by electrophoresis / western blot / ECL detection, and the 34th Val was further structurally analyzed. Was identified as a TPI mutated to IIe. This mutation is located in the vicinity of the melanoma-specific neoantigen, suggesting the possibility of a new pancreatic cancer-specific antigen. Next, the ELISA method was established and screening was carried out. The sera of healthy subjects had a detection sensitivity or less, and the quantitative values of pancreatic cancer were consistent with the PanIN classification, and it was considered that they could be applied to the differential test for pancreatic diseases.

Free Research Field

検査診断学

Academic Significance and Societal Importance of the Research Achievements

膵臓癌は、悪性新生物による死亡数の第４位を占め、発券時には既に浸潤・転移を伴う進行癌で極めて予後不良である。其処で、感度・特異度の高い分子マーカーを見出せれば、早期診断・根治療法の道が開ける。今回のTPIネオ抗原によるELISA法によるスクリーニングは鑑別診断への応用可能な検査技術の確立への大きな第一歩となるであろう。